Dextroamphetamine Treatment in Children With Hypothalamic Obesity.
craniopharyngioma
dextroamphetamine
genetic obesity
hypothalamic obesity
resting energy expenditure
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
12
2021
accepted:
09
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Hypothalamic obesity (HO) in children has severe health consequences. Lifestyle interventions are mostly insufficient and currently no drug treatment is approved for children with HO. Amphetamines are known for their stimulant side-effect on resting energy expenditure (REE) and suppressing of appetite. Earlier case series have shown positive effects of amphetamines on weight in children with acquired HO. We present our experiences with dextroamphetamine treatment in the, up to now, largest cohort of children with HO. A retrospective cohort evaluation was performed of children with HO treated with dextroamphetamine at two academic endocrine pediatric clinics. Off-label use of dextroamphetamine was initiated in patients with progressive, therapy-resistant acquired or congenital HO. Anthropometrics, REE, self-reported (hyperphagic) behavior and energy level, and side effects were assessed at start and during treatment. Nineteen patients with a mean age of 12.3 ± 4.0 years had been treated with dextroamphetamine. In two patients, ΔBMI SDS could not be evaluated due to short treatment duration or the simultaneous start of extensive lifestyle treatment. Mean treatment duration of the 17 evaluated patients was 23.7 ± 12.7 months. Fourteen patients ( In addition to supportive lifestyle interventions, dextroamphetamine treatment may improve BMI in children with HO. Furthermore, dextroamphetamines have the potential to decrease hyperphagia and improve resting energy expenditure, behavior, and energy level. In patients with acquired HO, these effects seem to be more pronounced when compared to patients with congenital HO. Future studies are needed to support these results.
Identifiants
pubmed: 35355559
doi: 10.3389/fendo.2022.845937
pmc: PMC8959487
doi:
Substances chimiques
Dextroamphetamine
TZ47U051FI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
845937Informations de copyright
Copyright © 2022 van Schaik, Welling, de Groot, van Eck, Juriaans, Burghard, Oude Ophuis, Bakker, Tissing, Schouten-van Meeteren, van den Akker and van Santen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Poult Sci. 1979 Nov;58(6):1619-24
pubmed: 119957
Nat Rev Endocrinol. 2010 Nov;6(11):609-18
pubmed: 20877295
Endocrine. 2018 Feb;59(2):364-372
pubmed: 29230635
J Clin Endocrinol Metab. 2003 Nov;88(11):5227-31
pubmed: 14602754
Physiol Rev. 1946 Oct;26(4):541-59
pubmed: 21002972
Cell. 1997 Jan 10;88(1):131-41
pubmed: 9019399
Hum Nutr Clin Nutr. 1985;39 Suppl 1:5-41
pubmed: 4044297
PLoS One. 2011;6(11):e27608
pubmed: 22110687
Prog Neurobiol. 2005 Apr;75(6):406-33
pubmed: 15955613
Exp Diabetes Res. 2012;2012:764017
pubmed: 22719753
Endocr Rev. 2019 Feb 1;40(1):193-235
pubmed: 30247642
J Pediatr Endocrinol Metab. 2006 Feb;19(2):129-34
pubmed: 16562585
Front Endocrinol (Lausanne). 2015 Feb 09;6:14
pubmed: 25709598
Ann Hum Biol. 1999 Jul-Aug;26(4):303-8
pubmed: 10462152
Pharmacol Rev. 2018 Oct;70(4):712-746
pubmed: 30087160
Obes Rev. 2021 Jul;22(7):e13210
pubmed: 33559362
J Clin Endocrinol Metab. 2010 Dec;95(12):5395-402
pubmed: 20826582
Clin Obes. 2021 Dec;11(6):e12481
pubmed: 34291582
Trends Cogn Sci. 2011 Jan;15(1):37-46
pubmed: 21109477
Arch Pediatr Adolesc Med. 2002 Sep;156(9):887-92
pubmed: 12197795
Dis Model Mech. 2017 Jun 1;10(6):679-689
pubmed: 28592656
Pediatrics. 2017 Sep;140(3):
pubmed: 28827377
J Physiol. 2009 Apr 1;587(Pt 7):1607-17
pubmed: 19221126
J Pediatr Endocrinol Metab. 2015 May;28(5-6):503-13
pubmed: 25781673
Obes Facts. 2019;12(1):91-102
pubmed: 30844799
Int J Obes (Lond). 2014 Jun;38(6):784-93
pubmed: 23999198
Front Syst Neurosci. 2015 Jun 15;9:90
pubmed: 26124708
Pediatr Obes. 2020 Jan;15(1):e12577
pubmed: 31670905
Int J Clin Pract. 2016 Mar;70(3):206-17
pubmed: 26811245
Obes Facts. 2020;13(4):361-370
pubmed: 32781455
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
CNS Drugs. 2008;22(3):213-37
pubmed: 18278977
J Psychopharmacol. 2014 Sep;28(9):866-73
pubmed: 24785761
Physiol Behav. 2006 Feb 28;87(2):221-44
pubmed: 16412483
Eur J Pharmacol. 2011 Jun 11;660(1):165-70
pubmed: 21211528
Expert Rev Neurother. 2018 Oct;18(10):793-806
pubmed: 30257123
Front Neurosci. 2013 Mar 27;7:36
pubmed: 23543912
J Pediatr Endocrinol Metab. 2015 Nov 1;28(11-12):1305-12
pubmed: 26203601
J Clin Endocrinol Metab. 2015 Feb;100(2):467-74
pubmed: 25375987
Nature. 1998 Mar 26;392(6674):398-401
pubmed: 9537324
Best Pract Res Clin Endocrinol Metab. 2014 Oct;28(5):725-37
pubmed: 25256767